MVIR Stock Chart

Medivir researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The Company's products portfolio includes Remetinostat for use in the treatment of cutaneous T-cell lymphoma; Birinapant in combination with Keytrudafor treating solid tumors; and MIV-711 for the treatment of osteoarthritis, as well as MIV-818, a preclinical stage nucleoside pro-drug for treating patients with advanced liver cancers. Its products also include drugs for the treatment of labial herpes and hepatitis C virus.